Allergan (AGN) Ratings, Outlook Affirmed by Fitch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Fitch Affirms Allergan at 'BBB-'; Outlook Stable
December 8, 2016 4:16 PM ESTCHICAGO--(BUSINESS WIRE)-- Fitch Ratings has affirmed the ratings of Allergan plc (Allergan; NYSE: AGN) and subsidiaries at 'BBB-'. The Rating Outlook is Stable.
A full list of rating actions, which apply to approximately $32.8 billion of debt outstanding at Sept. 30, 2016, follows at the end of this release.
KEY RATING DRIVERS
Scaled and Growing
Allergan is among the largest pharmaceutical companies in the world, with a diversified, durable, and growing product portfolio and a strong product pipeline. Fitch expects Allergan to generate mid- to high-single-digit organic sales growth, strengthened through strategic acquisitions, over the ratings horizon.... More
